Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

GP Exams > Cardiovascular Conditions > Flashcards

Cardiovascular Conditions Flashcards

1
Q

Abdominal aortic aneurysm (risk factors, history, differentials, surveillance, indications of repair)

A

Key points
● 65% of patients with a ruptured AAA die
● There is no routine screening in asymptomatic patients even with there is a strong family history
● If a patient is symptomatic then they should be investigated and referred to a vascular surgeon
Risk factor: > 65 years with history of peripheral vascular disease, advancing age, male, smoking, family history, atherosclerosis, HTN, hypercholesterolaemia, aneurysm.
History: smoking, chronic obstructive pulmonary disease, hypertension, genetic (Marfan and Ehlers-Danlos)
Differentials: renal calculus, diverticulitis, incarcerated hernia, lumbar spine disease.
Surveillance: 3-3.9 24 months, 4-4.5 12 months, 4.6-5 6 months, >5 3 months.
Indications for repair: >5.5 male, >5 female, change of >1 cm in 1 year, symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Acute pulmonary oedema

radiological findings, initial treatment pre-hospital vs. ED setting

A

Radiological findings - cardiomegaly, Kerley lines, azygos, pleural fluid.
Initial treatment (Pre-hospital)
1. Sit patient upright
2. Frusemide 20-80mg IV STAT and reassess in 20 mins
3. High-flow oxygen if SatO2 <94%
4. Consider GTN 400 mcg sublingual repeat every 5 min up to 1200 mcg IF SBP >100 mmHg
Initial treatment (ED setting)
1. Frusemide 20-80mg IV STAT and reassess in 20 mins
2. IF SBP >100 mmHGm GTN 10mcg/min IV infusion
3. CPAP (start 10cm of water pressure)
4. Morphine 1-2.5mg IV once only

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Aortic dissection (classification, mechanism, risk factors, presentation, investigations)

A

Classification: refer to page 53 of GP Study Notes
Mechanism: tear in the aortic intima.
Risk factors: age, male, hypertension, preexisting aortic aneurysm, connective tissue disorder, Turner syndrome,
trauma, cocaine use.
Presentation: anterior chest pain ‘tearing’ posterior chest or back pain.
Investigations: If stable = CT angiogram.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Atrial fibrillation - classification

A

First diagnosed - First episode, has not previously been diagnosed
Paroxysmal - Self-terminating within 48 hours (up to 7 days)
Includes episode that have been cardioverted back
Persistent - Last longer than 7 days
Includes those cardioverted after 7 days
Long-standing persistent - Lasts > 1 year with rhythm control
Permanent - Rhythm control not used because remaining in AF acceptable by patient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Atrial fibrillation (approach to management, rate control, anti-coagulation)

A

Approach to management
Goals: reduction of VTE/stroke risk, symptom relief, treatment of comorbidities.
Rate-control: appropriate in asymptomatic patients with normal LVEF.
Rhythm-control: appropriate in patients who are highly symptomatic or have LV dysfunction.
Treatment choice:
● Immediate cardioversion: haemodynamically unstable atrial fibrillation.
● Delayed cardioversion: haemodynamically stable, left atrial thrombus excluded.
● Rate or rhythm control: haemodynamically stable atrial fibrillation lasting less than 48 hours (low risk of VTE)

Rate control
Aim: HR < 110 bpm
First-line: beta blocker
● Atenolol 25 mg PO daily
● Use carvedilol, bisoprolol or metoprolol succinate in HF patients
Second-line: calcium channel blocker
● Diltiazem MR 180 mg PO daily
Left ventricular dysfunction:
● Amiodarone 200mg PO daily

Anti-coagulation
CHADSVASc
Benefit of treatment:
● Men with score >2
● Women with score >3
Valvular vs. non-valvular atrial fibrillation
Valvular
● Criteria: Moderate or severe mitral stenosis and/or mechanical heart valve
● Significance: increased risk of VTE or stroke
● Anticoagulation choice: warfarin
Non-valvular
● Have benefit from anti-coagulation
● Can use other oral agents aside from warfarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cardiac tamponade (triad, causes)

A

Triad: elevated JVP, pulsus paradoxus, muffled heart sounds.
Cause: any process that causes pericarditis.
● Viral
● Drugs (hydralazine, procainamide, isoniazid, minoxidil)
● Connective tissue disease - systemic lupus erythematosus, rheumatoid arthritis
● Uraemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Stable angina (definition, management)

A

Definition: precipitated by exertion, typical radiation to shoulder/jaw/inner arm, relieved by rest or GTN in 10 mins.

Management of acute episode in stable:
● GTN spray 400 microgram sublingual, every 5 mins in pain persists, up to total of 3 doses if tolerated
● If pain persists after 10 minutes despite two doses, take a third dose of GTN and call an ambulance.

Ongoing management:
● Atenolol or metoprolol 25mg daily OR,
○ Consider carvedilol or bisoprolol in there is an element of heart failure
● Diltiazem 180mg PO daily
○ Do not use in combination with beta-blocker due to risk of severe bradycardia and heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Acute chest pain - key points, initial therapy

A

Key points
● Consider AMI in all cases where a clear alternative diagnosis is not evident
● A normal ECG does not rule out AMI
● If a troponin is indicated then refer to ED

Initial therapy

  1. Aspirin 300mg PO (chewed or dissolved)
  2. If stable, GTN 400-800 microg sublingually every 5 mins (up to 3 doses)
  3. For pain, morphine 2.5mg IV
  4. Oxygen if SatO2 <94%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cardiac investigations (stress ECG, stress ECHO, myocardial perfusion imaging, coronary CTA, calcium scoring)

A

Key points
● CT angiogram is gold standard
Stress ECG
● ST-segment depression on stress
● 70% sensitive and specific for CAD in men (60% in women)
Stress echocardiography
● 80% sensitive and specific in men and women
● Predictive value is optimised in patients with intermediate pretest probability of having CAD.
Myocardial perfusion imaging
● Thallium or sestamibi used
● Indicates regions of reversible and irreversible MI
● Useful in patient with abnormal resting ECG (e.g. LBBB)
Coronary CT angiography
● Indications:
○ Undifferentiated chest pain, normal ECG and normal troponin
○ Continuing, stable chest symptoms and normal stress test
Calcium scoring
● Indication: asymptomatic patients with intermediate Framingham risk (i.e. CVD risk of 10-15% in next 5
years)
● Not MBS rebated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Familial hypercholesterolaemia (presentation, ddx, calculator tools, treatment)

A

Presentation: severely elevated LDL with xanthoma and strong family history of premature cardiovascular levels (men
<55, female <60)
Need to exclude: nephrotic syndrome, severe cholestasis, hypothyroidism
Calculator tools: Dutch Lipid Clinic Network Score
Treatment: Commence treatment at time of diagnosis. Generally started at 10 yrs in children.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Familial hypercholesterolaemia (medication options)

A

Ezetimibe
(10mg PO daily)
- Can lower LDL by 20-25% in combination with statin
- Modest reduction in cardiovascular events but no effect on mortality.
- ADR: muscle pain, mild elevation of ALT.

Statin 
- High potency:
● Atorvastatin 40mg PO daily
● Rosuvastatin 5mg PO daily
- LFTs: not indicated to monitor. Consider ceasing if ALT 3x upper limit on the second measurement.

Bile acid binding resin

  • Example: cholestyramine 4g PO daily
  • Often used in combination with statin.
  • Avoid in patients with high triglycerides.

Fibrates

  • Example: fenofibrate 145 mg PO daily (eGFR >60).
  • Lowers triglycerides, modest reduction in LDL.
  • Consider checking CK regularly if it is used in combination with statin.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Hypercholesterolaemia (non-pharmacological management)

A

Non-pharmacological options:
● Reduce intake of saturated and trans fats
● Replacing saturated fats with monounsaturated and polyunsaturated fats
● Increasing intake of soluble fibre
● Introducing plant sterol-enriched milk, margarine or cheese products
● Exercise and weight loss most effective and increased HDL levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Heart failure - key points

A

● HFrEF = LVEF <50%, HFpEF = LVEF >=50%
● ECHO (gold standard), BNP can be used if ECHO not available (repeat 3-6 months post-commencement of
therapy)
● ACEI/ARB, beta blockers and spironolactone have mortality benefits for HFrEF (up tp 50-60% reduction)
● Entresto should be commenced if LVEF <40%
● Ivabradine should be commenced for LVEF <35% (if HR > 70 bpm)
● Metoprolol succinate (sustained release)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Heart failure - classifications

A 
NYHA grading 
I = no limitations 
II = slight limitations 
III = marked limitations 
IV = unable to perform without discomfort
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Heart failure - diagnostic criteria

A

HFrEF

  • Symptoms +/- signs of heart failure
  • LVEF <50%

HFpEF

  • Symptoms +/- signs of heart failure
  • LVEF >50%
  • Objective evidence of relevant structural heart disease and/or diastolic dysfunction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Heart failure - diagnostic workup

A

** Refer to page 177 of GP Study Notes

17
Q

Heart failure - management

A

Algorithm
** Refer to page 178 of GP Study Notes

Medications
- Heart failure specific beta blockers: carvedilol (3.125mg BD), metoprolol succinate (12.5mg daily), bisoprolol (1.25mg
daily).
● Start low and double dose every 2 weeks until maximum tolerated dose reached
- Angiotensin receptor neprilysin inhibitor: entresto (LVEF <40%)
- Other: ivabradine (restricted to symptomatic systolic CHF w/ HR >=77bpm, LVEF <35% and NYHA class II/III).
- Diabetes: SGLT2 (i.e. empagliflozin) inhibitor if concurrent HF.

18
Q

Hypertension - principles of therapy, medications

A

Principles of therapy
1. Start with low-moderate dose of first line drug
Review every 4-6 weeks for tolerance, efficacy, adverse effects and adherence
2. If target not reached after 3 month then add a second agent from a different class at low-moderate dose
3. If target reached then review ever 3-6 months

Medications
● First-line (uncomplicated and non-pregnant): ACEI, ARB, CCB, thiazide and thiazide-like diuretics.
● Second-line: beta-blockers (unless history of HFrEF and/or CVD).

19
Q

Hypertension - medication profiles

A

ACEI (Perindopril 5mg PO daily)

  • Monitor for hypotension kidney impairment and hyperkalaemia.
  • Avoid combining diuretics and NSAID.
  • No need to cease if there is an increase in Cr (up to 25%) or potassium (normal range).
  • ADRs: cough, angioedema.
  • Indications: HFrEF, CKD, diabetes
  • Contraindication: pregnancy.

CCB (amlodipine 10mg PO daily)

  • ADRs: peripheral oedema
  • Indications: stable angine

Thiazide or thiazide-like diuretics (Hydrochlorothiazide
12.5mg PO daily or Indapamide 1.25mg PO
daily)
- Avoid in gout
- Associated with risk of new-onset diabetes in younger patients
- Indications: patients > 65 yrs

20
Q

Hypertension - pregnancy, combinations to avoid, factor for poor response

A

Pregnancy:
● Centrally acting antiadrenergic: Methyldopa (125mg PO BD) or clonidine (50 microg PO BD)
○ DO NOT stop clonidine suddenly due to risk of severe rebound hypertension
● Beta-blocker: Labetalol

Combinations to avoid:
● Diltiazem with beta-blocker (heart block)
● ACEI/ARB with K+ sparing diuretic (hyperkalaemia)
● ACEI with ARB (renal dysfunction)
● Verapamil with beta-blocker (heart block)

Factors for poor response:
● Non-adherence
● Undiagnosed secondary causes for hypertension
● Treatment resistance due to sleep apnoea
● Undisclosed use of alcohol or recreational drugs
● Unrecognised high salt intake
● NSAID use

21
Q

Hypertrophic cardiomyopathy (key points, clinical features, findings, ECG)

A

Key points
● Most commonly inherited cardiac disorders
● Number one cause of sudden cardiac death in young adults
Clinical features:
● Exertional syncope or presyncope
● Pulmonary congestion (exertional dyspnoea, fatigue, orthopnoea, paroxysmal nocturnal dyspnoea)
● Chest pain
● Palpitations (supraventricular or ventricular arrhythmias)
Physical findings: systolic ejection crescendo-decrescendo murmur, holosystolic murmur at apex and axilla, other
(apical precordial impulse displaced laterally).
ECG finding: asymmetrical septal hypertrophy
● Voltage criteria for LVH, deep narrow Q waves <40ms wide in the lateral leads, aVL and V5-6

22
Q

Immune thrombocytopenic purpura (triad, features, types, diagnostic criteria)

A

Triad: bruising + oral bleeding + epistaxis

Clinical features:
● Acute onset
● No systemic illness
● Isolated thrombocytopenia
● Easy bruising, epistaxis, bleeding gums
● Examination otherwise normal

Types
● Acute - usually in children, usually post-viral
● Chronic - autoimmune disorder, usually in adult women, all cases need referral

Diagnostic criteria:
● One of exclusion
● Only isolated thrombocytopenia without another apparent cause

23
Q

Metabolic syndrome (criteria)

A

Criteria: Any three of below criteria.

  • Elevated waist circumference (>94 men, >80 women)
  • Elevated triglyceride (>1.7)
  • Reduced HDL (<1 men, <1.3 women)
  • Elevated BP (SBP >130, DBP >85)
  • Elevated fasting glucose (>5.5)
24
Q

Myocarditis (cause, significant)

A

Causes:
● Viral - HIV, influenza A, adenovirus
● Bacterial - mycoplasma
● Immune mediated - sarcoidosis, SLE, Kawasaki’s disease
● Drugs/toxin - clozapine, amphetamines
Significance: Increased risk of arrhythmias, cardiac failure, cardiogenic shock and death in the acute setting. May
cause dilated cardiomyopathy.

25
Q

Pericardial effusion (imaging findings, examination, investigations)

A

Radiological finding: old-fashioned ‘water bottle sign’

Examination: in the absence of cardiac tamponade, physical signs are not sensitive or specific for pericardial effusion

Investigation: ECG and CXR (initial), ECHO (definitive).

26
Q

Absolute cardiovascular risk calculator

A

Good to assess risk in patients >45 years without known history of CVD.

Criteria already known to be linked with high risk:
● Diabetes and age > 60 years
● Diabetes with microalbuminuria
● Moderate or severe chronic kidney disease
● Previous diagnosis of familial hypercholesterolaemia
● Systolic BP >=180 or diastolic >=110
● Serum total cholesterol >7.5
● ATSI >74 years

27
Q

CVD and BP target

A

General: <140/90 (or lower if tolerated)
CVD: <140/90 (peripheral vascular disease), <130/80 (coronary heart disease and prevention in diabetes)
Diabetes: <130/80
CKD: <140/90 (or lower if tolerated)

28
Q

CVD and lipid targets

A 
***Same for everyone***
Total cholesterol: <4
HDL: > 1
LDL: < 2 (1.8)
Non-HDL-C: <2.5
Triglyceride: <2
29
Q

Raynaud phenomenon (key point, mechanism, trigger, presentation, management)

A

Key point
● Can be primary or secondary (suspect connective tissue disorder or malignancy if there are other signs)
Mechanism: vasospasm of the digits.
Triggers: cold.
Presentation: episodic blanching, cyanosis and then erythema. Can be painful.
Management:
● Treat the underlying cause (if there is one)
● Gloves, warm clothing, cessation of smoking, avoid beta blockers.
● Severe cases:
○ Amlodipine 5 mg PO daily
○ Nifedipine MR 30 mg PO daily

30
Q

Thoracic aortic aneurysm (findings, complications)

A

Radiological findings: widened mediastinum, convex tracheal displacement, right sided bulge = ascending aorta, left
sided bulge = descending aorta.
Complications:
● Aortic dissection
● Atherosclerotic thoracic aortic aneurysm

31
Q

Pulmonary embolism (tip, when to order D-dimer

A

Tip
● Superficial femoral vein is a DEEP vein

When to order D-dimer
- PERC rule positive

Imaging: CTPA (gold standard), VQ perfusion (pregnancy/severe renal failure)

Anticoagulation:
● Before - FBE, UEC, LFT, APTT, INR, bHCG (child-bearing age)
● Oral therapy (not first-line in pregnancy or cancer-related, no NOAC if eGFR <25-30)
○ Apixaban (CrCl>25) - 10 mg PO BD for 7 days, then 5 mg PO BD
○ Rivaroxaban (CrCl >30) - 15 mg PO BD for 21 days, then 20mg PO daily

*** If using dabigatran there is a need for bridging enoxaparin for 5 days prior to commencement

32
Q

Post-thrombotic syndrome (significance, presentation, prevention, treatment)

A

Significance: commonly associated complication following DVT and can result in venous ulcer.
Presentation: chronic dependent swelling and pain, discomfort on walking, skin discolouration.
Prevention: graduated compression stockings.
Treatment: supportive (pain relief, stockings).

33
Q

VTE - duration of treatment

A

Proximal DVT/PE with provoking factor removed
● 3 months and review

Isolated distal DVT
● 6 weeks and review

Unprovoked distal DVT and or proximal DVT/PE
● 3 months and review for ? cessation vs. ? indefinite continuation

34
Q

VTE - prevention

A

Aspirin 100 mg PO daily can decrease the rate of recurrence for unprovoked proximal DVT or PE.

35
Q

PICC-related venous thrombosis (RF, timeframe, presentation, management)

A

Risk factors: previous DVT, obesity, recent surgery, malignancy, critical illness, presence of comorbidities
Timeframe: develops 7-14 days from time of placement
Presentation: arm or forearm swelling, chest/upper arm vein dilation (obstruction bypass)
Management:
● Symptomatic - elevation and NSAIDs
● Anticoagulation - for at least 3 months
** Removal of functional PICC is not recommended because reinsertion is associated with higher risk of VTE.

36
Q

IVC-related thrombosis (imaging, management)

A

Imaging: ultrasound.
Management:
● Superficial phlebitis → cease infusion, remove IVC, symptom management (elevation, warm/cold
compresses, NSAIDs)
** Consider suppurative phlebitis, chemical phlebitis or extravasation injury if pain is not well controlled with NSAIDs.

GP Exams (27 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions